We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$123B
$361M 5.24%
1,145,695
+49,667
+5% +$14.9M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$340M 4.93%
9,511,900
-232,000
-2% -$8.71M
ARGX icon
3
argenx
ARGX
$53.8B
$330M 4.8%
886,928
-24,172
-3% -$8.95M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$265M 3.84%
2,613,300
-159,994
-6% -$16.6M
ISRG icon
5
Intuitive Surgical
ISRG
$122B
$247M 3.59%
968,786
+11,700
+1% +$2.88M
MRNA icon
6
Moderna
MRNA
$24.5B
$238M 3.46%
1,551,706
-30,622
-2% -$5.05M
INCY icon
7
Incyte
INCY
$23.4B
$205M 2.98%
2,840,500
-116,477
-4% -$9.11M
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$177M 2.57%
3,268,000
-74,236
-2% -$3.59M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$177M 2.57%
883,250
-37,963
-4% -$7.98M
BSX icon
10
Boston Scientific
BSX
$65.4B
$172M 2.5%
3,439,579
-463,345
-12% -$21.8M
ABT icon
11
Abbott
ABT
$175B
$167M 2.42%
1,646,916
-37,563
-2% -$3.97M
SYK icon
12
Stryker
SYK
$123B
$138M 2.01%
484,774
-7,460
-2% -$1.98M
SAGE
13
DELISTED
Sage Therapeutics
SAGE
$130M 1.88%
3,090,000
+120,722
+4% +$5.19M
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
$104M 1.51%
1,911,861
+5,400
+0.3% +$315K
PODD icon
15
Insulet
PODD
$11.4B
$103M 1.5%
323,594
-22,186
-6% -$6.58M
RVMD icon
16
Revolution Medicines
RVMD
$39.6B
$103M 1.49%
4,747,900
-107,262
-2% -$2.64M
MDT icon
17
Medtronic
MDT
$106B
$99.1M 1.44%
1,229,235
+610,815
+99% +$49.8M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.36B
$92.2M 1.34%
4,013,500
-43,292
-1% -$1.15M
UNH icon
19
UnitedHealth
UNH
$387B
$92.1M 1.34%
194,811
-29,483
-13% -$14.2M
SRPT icon
20
Sarepta Therapeutics
SRPT
$1.82B
$89.1M 1.29%
646,614
-46,595
-7% -$6.04M
INSP icon
21
Inspire Medical Systems
INSP
$1.46B
$88.3M 1.28%
377,068
-24,674
-6% -$6.24M
DXCM icon
22
DexCom
DXCM
$29.6B
$87.7M 1.27%
755,079
-233,397
-24% -$26.1M
BDX icon
23
Becton Dickinson
BDX
$43.6B
$86.2M 1.25%
348,043
+16,483
+5% +$4.03M
EW icon
24
Edwards Lifesciences
EW
$49.4B
$86.1M 1.25%
1,040,669
-23,462
-2% -$1.84M
DHR icon
25
Danaher
DHR
$144B
$85M 1.23%
380,577
-32,666
-8% -$7.43M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.